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Research
Differing time dependencies of object recognition
memory impairments produced by nicotinic and
muscarinic cholinergic antagonism in perirhinal cortex
Chris J. Tinsley,1,3 Nadine S. Fontaine-Palmer,1 Maria Vincent,1 Emma P.E. Endean,1
John P. Aggleton,2 Malcolm W. Brown,1 and E. Clea Warburton1
1MRC Centre for Synaptic Plasticity, School of Physiological Sciences, Bristol University, Bristol BS8 1TD, United Kingdom;
2School of Psychology, Cardiff University, Cardiff CF10 3AT, United Kingdom
The roles of muscarinic and nicotinic cholinergic receptors in perirhinal cortex in object recognition memory were com-
pared. Rats’ discrimination of a novel object preference test (NOP) test was measured after either systemic or local infusion
into the perirhinal cortex of the nicotinic receptor antagonist methyllycaconitine (MLA), which targets alpha-7 (a7)
amongst other nicotinic receptors or the muscarinic receptor antagonists scopolamine, AFDX-384, and pirenzepine.
Methyllycaconitine administered systemically or intraperirhinally before acquisition impaired recognition memory
tested after a 24-h, but not a 20-min delay. In contrast, all three muscarinic antagonists produced a similar, unusual
pattern of impairment with amnesia after a 20-min delay, but remembrance after a 24-h delay. Thus, the amnesic
effects of nicotinic and muscarinic antagonism were doubly dissociated across the 20-min and 24-h delays. The same
pattern of shorter-term but not longer-term memory impairment was found for scopolamine whether the object preference
test was carried out in a square arena or a Y-maze and whether rats of the Dark Agouti or Lister-hooded strains were used.
Coinfusion of MLA and either scopolamine or AFDX-384 produced an impairment profile matching that for MLA. Hence,
the antagonists did not act additively when coadministered. These findings establish an important role in recognition
memory for both nicotinic and muscarinic cholinergic receptors in perirhinal cortex, and provide a challenge to simple
ideas about the role of cholinergic processes in recognition memory: The effects of muscarinic and nicotinic antagonism
are neither independent nor additive.
[Supplemental material is available for this article.]
Much evidence indicates that the perirhinal cortex is critically
involved in object recognition memory (for reviews, see Murray
and Bussey 1999; Brown and Aggleton 2001; Mumby 2001;
Aggleton and Brown 2006; Mumby et al. 2007; Aggleton et al.
2010; Brown et al. 2010; Winters et al. 2010). Recognition mem-
ory is impaired by lesions of the perirhinal cortex (Zola-Morgan
et al. 1989; Gaffan and Murray 1992; Meunier et al. 1993, 1996;
Mumby and Pinel 1994; Ennaceur et al. 1996; Winters et al.
2004) or by local perirhinal infusions of glutamatergic receptor
antagonists (Winters and Bussey 2005; Barker et al. 2006b).
The cholinergic system is widely hypothesized to play a
prominent role in mechanisms of memory and attention (for
reviews, see Voytko 1996; Sarter and Bruno 1997; Easton and
Parker 2003; Sarter et al. 2003; Hasselmo and Giocomo 2006;
Hasselmo and Stern 2006; Dani and Bertrand 2007). Nicotinic
and muscarinic receptors are located on neurons in the cerebral
cortex, including perirhinal cortex (Saleem et al. 2007).
Nicotinic receptor subunits form ligand-gated ion channels
(Sargent 1993), while muscarinic receptors are G-protein linked
(Wess 1993). Most nicotinic receptor subtypes are permeable to
Na+ and K+ ions, but the alpha-7 (a7) subtype is of particular
interest because it is also permeable to Ca2+ ions (Seguela et al.
1993) and has been linked to second messenger pathways impor-
tant in plasticity and memory formation (Bitner et al. 2007).
Indeed, it has been claimed that a7 nicotinic receptors play a
role in hippocampal LTP (Matsuyama et al. 2000; Chen et al.
2006) and the nicotinic antagonist methyllycaconitine (MLA)
that acts against a7, as well as other nicotinic receptors (Mogg
et al. 2002), has been shown to inhibit hippocampal LTP induc-
tion (Freir and Herron 2003; Chen et al. 2006). In perirhinal cor-
tical slices, the broad spectrum muscarinic receptor antagonist
scopolamine blocks LTD but not LTP (Warburton et al. 2003)
and application of the cholinomimetic carbachol induces a long-
lasting depression (Massey et al. 2001). The role of nicotinic,
including a7 receptors in perirhinal plasticity, is unknown.
It has been reported previously that scopolamine can impair
familiarity discrimination (Huston and Aggleton 1987; Ennaceur
and Meliani 1992; Bartolini et al. 1996; Besheer et al. 2001;
Norman et al. 2002; Warburton et al. 2003; Winters et al. 2007),
including when infused directly into the perirhinal cortex in
monkeys (Tang et al. 1997) or rats (Abe and Iwasaki 2001;
Warburton et al. 2003; Winters et al. 2007). However, studies of
nicotinic receptors have chiefly investigated agonist actions and
none have determined the role of antagonists within the perirhi-
nal cortex (Van Kampen et al. 2004; Boess et al. 2007; Pichat et al.
2007). In the experiments reported here, the effect upon recogni-
tion memory of MLA, which strongly antagonizes a7 nicotinic
but may also antagonize other nicotinic receptors (Mogg et al.
2002), has been compared with that of the broad-spectrum mus-
carinic antagonist scopolamine. The actionswere found to doubly
dissociate across 20-min and 24-h time delays. As this result was
unexpected and the effect of scopolamine was not in accord
3Corresponding author.
E-mail chris.tinsley@ntu.ac.uk.
Article is online at http://www.learnmem.org/cgi/doi/10.1101/lm.2274911.
18:484–492 # 2011 Cold Spring Harbor Laboratory Press
ISSN 1549-5485/11; www.learnmem.org
484 Learning & Memory
 Cold Spring Harbor Laboratory Press on June 24, 2011 - Published by learnmem.cshlp.orgDownloaded from 
with a previous study, further experiments were performed with
AFDX-384 (at a concentration designed to act also as a broad-
spectrummuscarinic antagonist) (Dorje et al. 1991), scopolamine
using variants of the basic experimental conditions, and the
selective M1 muscarinic antagonist pirenzepine. Additionally, to
determine whether impairment at both 20 min and 24 h could
be produced by combining muscarinic with nicotinic antago-
nism, the effects of coadministration were sought. The findings
established an unusual double dissociation in the effects of
muscarinic and nicotinic antagonism that provides a challenge
to simple ideas about the role of cholinergic processes in recogni-
tion memory.
Results
To establish the role of nicotinic and muscarinic receptors in rec-
ognition memory, the effects of systemic administration or local
infusions of the nicotinic antagonist MLA or muscarinic antago-
nists into the perirhinal cortex were determined on the rats’ pref-
erential exploration of a novel compared with a familiar object.
Systemic injections or perirhinal infusions (see Fig. 1B for infusion
sites) of vehicle or antagonist were made 30 min (systemic) or
15 min (local infusion) prior to the acquisition phase of the object
recognition test with the choice (test) phase being at a delay of
either 20 min or 24 h. The discrimination ratio (DR) at test was
calculated by dividing the difference in time exploring the novel
and the familiar object by the time taken exploring both objects.
All rats under control conditions showed significant discrim-
ination at all time intervals (t-tests, P ≤ 0.05). Additionally, the
total time exploring objects in the acquisition or choice phases
showed no significant differences dependent on whether the ani-
mals had received vehicle or cholinergic antagonists (Table 1).
Experiment 1 investigated the effect of nicotinic receptor
antagonism.
Experiment 1: Object recognition memory following
administration of the nicotinic receptor antagonist MLA
Figure 2 shows that MLA impaired recognitionmemory at a delay
of 24 h, but not at a delay of 20 min, whether administration was
systemic (87.5 mg/kg)or local via cannula infusion (0.0875 ng/mL)
into the perirhinal cortex.
Analyzing across all of the MLA conditions, three factor
ANOVA (delay [20 min or 24 h], administration route [systemic
injection or intracerebral infusion], treatment [vehicle or drug])
revealed a significant effect of treatment (F(1,40) ¼ 6.62, P ¼
0.01), and a significant interaction of treatment by delay
(F(1,40) ¼ 4.61, P ¼ 0.04). Data for the two delays were therefore
analyzed separately.
For the 20-min delay tests, two factor ANOVA (administra-
tion route, treatment) showed no significant effect of treatment
(F(1,20) , 1, P ¼ 0.8) and no significant interaction of administra-
tion route by treatment (F(1,20) , 1, P ¼ 0.4). TheMLA-treated ani-
mals showed significant discrimination in the test (DR. 0: t-test,
systemic injection: P ¼ 0.001; intracerebral infusion: P ¼ 0.001).
For the 24-h delay tests, two factor ANOVA (administra-
tion route, treatment) showed a significant effect of treatment
(F1,20 ¼ 15.17, P ¼ 0.001) and no significant interaction of ad-
ministration route by treatment (F(1,20) ¼ 2.00, P ¼ 0.2). Post-hoc
analysis for the 24-h tests with ANOVAs showed a significant
impairment in the MLA-treated rats compared with controls (sys-
temic injection: F(1,9) ¼ 7.74, P ¼ 0.02; intracerebral infusion:
F(1,11) ¼ 7.48, P ¼ 0.02); the MLA-treated animals did not show
significant discrimination in the test (DR ¼ 0: t-test, systemic
injection: P ¼ 0.3; intracerebral infusion: P ¼ 0.4).
As previously reported work (Warburton et al. 2003; Winters
et al. 2006) had not looked at the effects of muscarinic antago-
nism at both 20-min and 24-h delays under the same experimen-
tal conditions, to allow direct comparisonwith the effects ofMLA,
Experiment 2 sought the effects of the broad spectrummuscarinic
antagonist scopolamine under the same experimental conditions
as for MLA.
Experiment 2: Object recognition memory following
administration of the muscarinic receptor antagonist
scopolamine
Figure 3 reveals that scopolamine impaired recognition memory
at a delay of 20 min, but not at a delay of 24 h, whether adminis-
tration was systemic (0.05 mg/kg) or local via cannula infusion
(0.05 ng/mL) into the perirhinal cortex.
Analyzing across all ofthe scopolamine conditions, three
factor ANOVA (delay [20 min or 24 h], administration route [sys-
temic injection or intracerebral infusion], treatment [vehicle or
drug]) revealed a significant effect of treatment (F(1,39) ¼ 13.67,
P ¼ 0.001) and a significant interaction
of treatment by delay (F(1,39) ¼ 10.27,
P ¼ 0.003). Data for the two delays were
therefore analyzed separately.
For the 20-min delay tests, two
factor ANOVA (administration route,
treatment) showed a significant effect
of treatment (F(1,20) ¼ 15.49, P ¼ 0.001)
and no significant interaction of admin-
istration route by treatment (F(1,20), 1,
P ¼ 0.7). The scopolamine-treated ani-
mals did not show significant discri-
mination in the test (DR. 0: t-test,
intracerebral infusion: P ¼ 0.5, systemic
injection: P ¼ 0.5).
For the 24-h delay tests, two fac-
tor ANOVA (administration route, treat-
ment) showed no significant effect of
treatment (F(1,19) , 1, P ¼ 0.6) and no
significant interaction of administra-
tion route by treatment (F(1,19) ¼ 1.19,
P ¼ 0.3). The scopolamine-treated ani-
mals showed significant discrimination
Figure 1. Site of intracerebral infusions into the perirhinal cortex. (A) Cresyl violet-stained section
showing the track mark of the guide cannula (20˚ from vertical—see dashed line) and the infusion
site within the perirhinal cortex (rhinal sulcus is marked by the black triangle). (B) Reconstructed indi-
vidual infusion sites from the 25 animals included in the analysis from Experiments 1–5 shown on a rep-
resentative brain section at 25.8 with respect to bregma (Paxinos and Watson 1998). Black squares
indicate the tip of the guide cannula (note some symbols may overlap). All cannulae were accurately
located in the perirhinal cortex.
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in the test (DR. 0: t-test, intracerebral infusion: P ¼ 0.001, sys-
temic injection: P ¼ 0.001).
The deficit at 20 min for scopolamine replicated the findings
of Warburton et al. (2003). However, the failure to find a clear
impairment with scopolamine at a 24-h delay conflicts with the
findings ofWinters et al. (2006).Winters et al. (2006) investigated
the effects of scopolamine using a Y-maze and Lister Hooded rats.
In studies reported in the Supplementary Material (Experiments
1SA,B; Figs. 1SA,B), the same pattern of memory loss, with impair-
ment at 20 min, but unimpaired performance at 24 h, was found
using a Y-maze or using Lister Hooded rats, thereby confirming
the findings of Experiment 2. As the pattern of scopolamine-
induced impairmentwasunusual, Experiment 3 testedbroad-spec-
trum muscarinic antagonism produced by a different compound,
AFDX-384.
Experiment 3: Object recognition
memory following intraperirhinal
infusion of the muscarinic receptor
antagonist AFDX-384
To determine whether the unusual pat-
tern of impairment produced by sco-
polamine was replicable with a different
muscarinic antagonist, experiments were
undertaken using the AFDX-384 at a
dose sufficiently high to antagonize all
muscarinic receptor subtypes (Dorje
et al. 1991). Administration was by local
perirhinal infusion (12 ng/mL), and
Dark Agouti rats were tested in the arena.
Figure 4 reveals that AFDX-384
produced the same pattern of memory
deficit as scopolamine: impairment at
20 min, but not 24 h. An overall analysis
by two factor ANOVA (delay [20 min
or 24 h], treatment [vehicle or drug])
revealed a near-significant effect of
treatment (F(1,15) ¼ 4.35, P ¼ 0.06) and a
near-significant interaction of treatment
by delay (F(1,15) ¼ 4.16, P ¼ 0.06). To
allow closer comparison with the find-
ings for scopolamine, data for the two
delays were analyzed separately.
For the 20-min delay, the post hoc
analysis showed significant impairment
for the muscarinic antagonist-treated
animals compared with controls (ANOVA: F(1,8) ¼ 7.64, P ¼
0.02); the AFDX-384-treated animals did not show significant dis-
crimination (DR ¼ 0: t-test: P ¼ 0.4).
For the 24-h delay, the post hoc analysis showed no sig-
nificant impairment for the muscarinic antagonist-treated ani-
mals compared with controls (ANOVA: F(1,7) ¼ ,1, P . 0.9); the
AFDX-384-treated animals showed significant discrimination
(DR. 0: t-test, AFDX-384: P ¼ 0.006).
To further investigate the unusual pattern of impairment
produced by scopolamine and AFDX-384, the experiment was
repeatedwith the selectiveM1muscarinic receptor antagonist pir-
enzepine. Pirenzepine produced the same pattern of memory def-
icit as scopolamine and AFDX-384: impairment at a 20-min, but
not a 24-h delay (see Supplemental Material).
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Figure 2. Effect of methyllycaconitine (MLA) on object recognition memory at 20-min or 24-h delays
tested in Dark Agouti rats in the arena. (A) Effect of systemic injection of MLA (87.5 mg/kg, ip). MLA
impaired memory after a 24-h (A2) but not a 20-min (A1) delay. (B) Effect of intraperirhinal infusion
(0.0875 ng/mL) of MLA. Again, MLA impaired memory after a 24-h (B2), but not after a 20-min (B1)
delay. (∗) P, 0.05.
Table 1. Exploration of animals in the acquisition and choice phases
Experiment 1 Experiment 2 Experiment Experiment 4
Infusate
type Trial Delay
(A) (B) (A) (B) 3 (A) (B)
MLA
(systemic)
MLA
(cannula)
scop
(systemic)
scop
(infusion) AFDX-384 MLA + Scop MLA + AFDX-384
Vehicle Acquisition 20 min 32(3) 32(2) 32(3) 32(2) 25(3) 30(2) 24(1)
Vehicle Acquisition 24 h 31(2) 37(1) 31(3) 26(3) 30(3) 29(3) 30(1)
Vehicle Choice 20 min 27(4) 21(3) 29(3) 15(2) 14(3) 17(2) 13(2)
Vehicle Choice 24 h 26(2) 34(2) 25(2) 17(1) 16(1) 13(2) 10(0)
Drug Acquisition 20 min 36(2) 29(2) 36(2) 29(3) 30(2) 29(3) 24(1)
Drug Acquisition 24 h 33(2) 35(2) 30(3) 26(2) 32(3) 29(2) 32(3)
Drug Choice 20 min 33(4) 24(3) 26(3) 16(2) 16(2) 15(1) 11(3)
Drug Choice 24 h 21(2) 33(1) 26(2) 19(1) 20(4) 14(2) 9(2)
Values shown are mean time exploring both objects in seconds (SEM) for vehicle or drug at each of the time-points investigated. For acquisition trials, three
factor ANOVA (treatment, route/dose, delay) for Experiments 1 and 2, or two factor ANOVA for Experiments 3, 4A, or 4B, (treatment, delay) revealed no signifi-
cant effects across any of the experimental groupings. Similarly, for choice trials, three factor ANOVA and two factor ANOVA revealed no significant effects
across any of the experimental groupings.
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Given the different impairments found with nicotinic and
muscarinic antagonism, it was predicted that coadministration
of both types of antagonist should produce an impairment at
both long and short delays: this was tested in Experiment 4.
Experiment 4: Object recognition memory following
combined intraperirhinal infusion of MLA and a
muscarinic antagonist
To test the expectation of impairment at both delays, MLA was
coinfused with scopolamine or AFDX-384 at the doses previously
used. Figure 5 shows the results after Dark Agouti rats were tested
in the square arena.
Analyzing across all of the con-
ditions, three factor ANOVA (delay
[20 min or 24 h], drug combination
[MLA + scop, MLA + AFDX-384], treat-
ment [vehicle or drug]) revealed a sig-
nificant effect of treatment (F(1,35) ¼
18.81, P, 0.001) and a significant inter-
action of treatment by delay (F(1,35) ¼
4.02, P ¼ 0.05). For the 20-min delay
test, two factor ANOVA (drug combina-
tion [MLA + scop, MLA + AFDX-384],
treatment [vehicle or drug]) showed no
significant effect of treatment (F(1,17) ¼
2.69, P ¼ 0.12) and no significant inter-
action of treatment by drug combination
(F(1,17) ¼ ,1, P ¼ 0.7). For the 24-h delay
test, two factor ANOVA (drug combi-
nation [MLA + scop, MLA + AFDX-384,
MLA + pirenzepine], treatment [vehicle
or drug]) showed a significant effect of
treatment (F(1,18) ¼ 20.37, P, 0.001)
and no significant interaction of treat-
ment by drug combination (F(1,18) , 1,
P ¼ 0.7). Hence, in each case the pattern
of impairment mirrored that produced
by MLA with impairment only at the
24-h delay rather than there being an
impairment at both delays.
The results for the individual drug
coadministrations are as follows. At the
20-min delay there was no significant
effect of treatment (all Ps . 0.1) for
MLA plus scopolamine or MLA plus
AFDX-38. In each case the drug
group showed significant discrimination
(DR. 0; P . 0.01). At the 24-h delay
there was a significant effect of treatment
for MLA plus scopolamine (ANOVA,
F(1,11) ¼ 12.93, P ¼ 0.004), and MLA
plus AFDX-38 (ANOVA, F(1,7) ¼ 9.82,
P ¼ 0.02). In both cases the drug group
failed to show significant discrimination
(DR. 0; P . 0.2).
Taken together, the results for co-
application of MLA and muscarinic
antagonists (scopolamine or AFDX-384)
provide evidence against an additive
effect for antagonism of nicotinic recep-
tors and muscarinic receptors. Coinfu-
sions of MLA and scopolamine, or MLA
and AFDX-384 all blocked memory after
a 24-h but not a 20-min delay. Hence,
addition of the muscarinic antagonist
did not alter the profile of impairment produced by MLA admin-
istered alone, so that MLA appeared to override the effect of mus-
carinic antagonism.
Discussion
The results demonstrate a double dissociation in the effects of
nicotinic and muscarinic receptor antagonism on object recogni-
tion memory measured at 20-min and 24-h delays. Nicotinic
antagonism does not impair memory measured after 20 min,
but does impair memory after 24 h, whereas blockade of muscar-
inic receptors impairs memory after 20 min, but not after 24 h.
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Figure 3. Effect of scopolamine on object recognition memory at 20 min and 24 h tested in Dark
Agouti rats in the arena. (A) Effect of systemic injection of scopolamine (0.05 mg/kg, ip) prior to
object recognition memory testing. Scopolamine impaired memory at a 20 min (A1) but not at a
24 h (A2) delay. (B) Effect of intraperirhinal infusion of scopolamine (0.05 ng/mL) prior to object recog-
nition memory testing. Scopolamine impaired memory at a 20-min (B1) but not at a 24-h (B2) delay. (∗)
Significance of ANOVA test at P, 0.05.
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Figure 4. Effect of the muscarinic antagonist AFDX-384 on recognition memory at 20-min and 24-h
delays tested in Dark Agouti rats in the arena. Intraperirhinal infusion of AFDX-384 (12 ng/mL) to object
recognition memory prior to object recognition memory testing impaired memory after a 20-min (A1),
but not a 24-h (A2) delay.
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Coapplication of the nicotinic antagonist MLA and a muscarinic
antagonist resulted in impairment at a delay of 24 h, but not at
20 min.
Effect of nicotinic antagonism on object recognition
memory
The results demonstrate that when given so as to be active during
acquisition, MLA impairs object recognition memory after 24 h,
but not after 20 min. MLA has a well-documented action antago-
nizing neuronal a-bungarotoxin binding sites (Ward et al. 1990),
which are known to reside primarily on a7 receptors (Davies et al.
1999;Whiteaker et al. 1999). However, there is evidence thatMLA
may also act at a3b2 and a4b2 nicotinic binding sites (Mogg et al.
2002). Accordingly, contributions to the effects produced byMLA
on recognition memory by actions at a4b2 containing nicotinic
receptors cannot be excluded. Effects from action at the a3b2
site are less likely, as a3b2 subunits are not among the main
nicotinic receptor subunits in rodent cortex (Gotti et al. 2006).
The profile of long-term (24-h) but not shorter-term (20-min)
memory impairment produced by MLA is the same as that found
with NMDA receptor antagonism (Barker et al. 2006b), metabo-
tropic glutamate receptor antagonism (Barker et al. 2006a),
L-type voltage-dependent calcium channel blockade (Seoane
et al. 2009), and calcium calmodulin-dependent kinase II
(CAMKII) antagonismwith KN-62 or autocamtide-2 related inhib-
itory peptide (AIP) (Tinsley et al. 2009). A previous study (Pichat
et al. 2007) found no effect ofMLA on object recognitionmemory
at a 1-h delay, though MLA administered intracerebroventricu-
larly in rats has been reported to impair social recognition
memory at a 15-min delay (Van Kampen et al. 2004). Further,
the a7 receptor agonist, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-
(methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF), enhances
social recognition memory after a 24-h delay, this enhancement
being blocked byMLA (Boess et al. 2007). As the effects of infusing
MLA after acquisition were not tested in the present study, it is
possible that the memory deficit at a
24-h delay is due to consolidation rather
than acquisition mechanisms. Scopol-
amine given after acquisition or so as to
be active during retrieval does not pro-
duce an impairment inobject recognition
memory at a 20-min delay (Warburton
et al. 2003); hence, this memory impair-
ment can be ascribed to antagonism of
muscarinic receptors during acquisition,
rather than actions on retrieval or consol-
idationmechanisms.
Effect of muscarinic antagonism on
object recognition memory
Muscarinic antagonism impaired object
recognition memory after a 20-min
delay, but not after a 24-h delay. This
same unusual pattern of impairment
was found for scopolamine, AFDX-384,
and pirenzepine. Pirenzepine produced
a parallel pattern of impairment to sco-
polamine (see Supplemental Material),
suggesting that the dependency of the
deficit is dependent upon M1 rather
than other subtypes of muscarinic
receptors. The same pattern of deficit
was found for both systemic and local
perirhinal infusions of scopolamine,
in both Dark Agouti and Lister Hooded rat strains (see
Supplemental Material). Such a counterintuitive pattern of
impairment with amnesia being followed by remembrance has
also been described when perirhinal kainate receptors are an-
tagonized (Barker et al. 2006b). AFDX-384 given systemically
(1 mg/kg—lower than the dose used in the current experiments)
has previously been reported to have no effect on object re-
cognition memory with a 1-h delay (Vannucchi et al. 1997).
Impairments of object recognition memory by scopolamine
have been reported for delays of 20 min (Warburton et al. 2003),
1 h (Vannucchi et al. 1997), 3 h (Dodart et al. 1997), and 24 h
(Winters et al. 2006). In unpublished experiments in Bristol
(Fontaine-Palmer 2008) scopolamine was found to impair object
recognition memory after a delay of 1 h (in agreement with
Vannucchi et al. 1997) or 3 h (Dodart et al. 1997), but not after
a delay of 6 h. We have found no reports of the effects of scopol-
amine on recognition memory at long (.3 h) delays in either
monkeys or humans, but there are reports of impairment in mon-
keys at short delays (Aigner et al. 1991; Tang et al. 1997; Turchi
et al. 2008; but, see Browning et al. 2010).
The lack of impairment found here for muscarinic antago-
nism at the 24-h delay contrasts with the previously reported
scopolamine-induced impairment at that delay (Winters et al.
2006). However, in that study (Winters et al. 2006), the scopol-
amine-induced impairment was partial and the scopolamine-
treated animals’ discrimination was similar to that of other
control groups in the study, albeit lower than that of its particular
matched control group. There are several procedural differences
between the two studies, including rat strain, testing arena shape,
and precise details of cannulae implantation. Neither rat strain
nor testing arena shape appear able to explain the pattern of
impairment: In the present experiments, using systemic adminis-
tration, no impairment for a 24-h delay was found for Dark Agouti
rats in a square arena or in a Y-maze such as used byWinters et al.
(2006) and neither was impairment found for Lister Hooded rats,
such as used byWinters et al. (2006), when tested in a square arena
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Figure 5. Effect of coinfusion of muscarinic antagonists and MLA on object recognition memory at
20-min or 24-h delays in Dark Agouti rats tested in the arena. (A) Effect of intraperirhinal infusion of sco-
polamine with MLA prior to object recognition memory testing. Scopolamine with MLA did not impair
memory at a 20-min (A1), but did at a 24-h (A2) delay. (B) Effect of intraperirhinal infusion of AFDX-384
with MLA prior to object recognition memory testing. AFDX-384 with MLA did not impair memory at a
20-min (B1), but did at a 24-h (B2) delay. (∗) P, 0.05.
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(see Supplemental Material). The angle of approach of infusion
cannulae differs in the two studies, though coordinates within
perirhinal cortex appear to overlap: Winters and colleagues used
a vertical approach, whereas our cannulae were angled at 20˚ to
the vertical; however, if used as a basis for explanation, there
would then be generated a discrepancy between the results for sys-
temic and intracerebral administration routes. The dose of scopol-
amine (0.05 ng/mL; 130 nM) in the present experimentswas lower
than that (10 mg/mL; 26 mM) used by Winters et al. (2006) or
Warburton et al. (2003). The lower dose was chosen so as to be
closer to the reported Ki values (0.3–2 nM) (Huang et al. 2001)
for scopolamine and thereby avoid any significant increase in
osmolarity and possible nonselective effects. Nevertheless, experi-
ments performed with infusion of 10 mg/mL of scopolamine (data
not included), as used in previous reports, produced the same pat-
tern of results as the lower dose (significant impairment at 20 min,
and no impairment at 24 h).
The effect of coinfusing a7 nicotinic and muscarinic
antagonists on object recognition memory
In the current experiments, when muscarinic antagonists were
coapplied with the nicotinic receptor antagonist MLA, memory
was blocked after a 24-h delay, but memory after a 20-min delay
was unimpaired. In each instance, the dose of the muscarinic
antagonist given alone was sufficient to produce amnesia at the
shorter (20-min) delay. Hence, unexpectedly, for memory after a
20-min delay, addition of a potentially amnesic dose of a muscar-
inic antagonist to a potentially amnesic dose of a nicotinic antag-
onist removed the impairment produced by the single dose of the
muscarinic antagonist. Accordingly, the effects of giving a mus-
carinic and an a7 nicotinic antagonist together were not additive:
The anticipatedmemory impairment at both 20 min and 24 hwas
not seen. Titrating dosages of antagonists against each other was
not an objective of the current experiments, so it remains to be
discovered whether there are doses of a nicotinic plus a muscar-
inic antagonist that would result in impairment at both 20-min
and 24-h delays. (However, coinfusion of MLA with a very high
dose of scopolamine [10 mg/mL] left an impairment at the
20-min delay, but did not produce impairment at the 24-h delay
[data not included].) These findings were unexpected and provide
a challenge to simple ideas about the action of cholinergic recep-
tors in recognitionmemory: Clearly, the effects ofmuscarinic and
nicotinic antagonism are neither independent nor additive. We
have not found reports that scopolamine has agonistic/antago-
nistic effects onnicotine receptors or thatMLAhas effects onmus-
carinic receptors. However, there are multiple opportunities for
interactions involving the two types of antagonism, for example,
involving presynaptic autoreceptors or alterations in the balance
of excitation and inhibition in local circuits. Indeed, there is
evidence of interactions involving the two types of receptors:
The muscarinic receptor antagonist atropine can either inhibit
or potentiate the responses of nicotinic receptors (Zwart and
Vijverberg 1997; Parker et al. 2003; Gonzalez-Rubio et al. 2006).
Moreover, an interaction between an a7 agonist and scopolamine
has been reported previously: The a7 agonist AR-R 17779 reverses
the scopolamine-induced impairment in social recognition
memory seen at a 15-min delay in rats (Van Kampen et al.
2004). Additionally, AFDX-384 has been reported to reverse the
scopolamine-induced impairment of recognition memory at a
delay of 1 h (Vannucchi et al. 1997), so that interactions amongst
cholinergic receptor subtypes are potentially complex. Eventual
explanation of the effects of coadministration found in the cur-
rent experiments is likely to depend on an understanding of the
balance of excitation and inhibition produced by specific choli-
nergic receptor activations in local perirhinal networks.
The different temporal patterns of impairment produced by
antagonism of muscarinic and nicotinic cholinergic receptors in
perirhinal cortex mirror those previously described for kainate
and N-methyl-D-aspartate (NMDA) glutamate receptor antago-
nism (Barker et al. 2006b). A potential explanation for these
results is provided by following the argument given by Barker
et al. (2006b): They suggested that muscarinic (as well as kainate)
receptor activation is necessary for the plastic processes of fast-
changing perirhinal neuronal responses (“novelty” and “recency”
responses) (Xiang and Brown 1998) that are hypothesized to sup-
port shorter-term (20-min delay)memory, while nicotinic (as well
as NMDA) receptor activation is necessary for the plastic processes
of slow-changing perirhinal neuronal responses (“familiarity”
responses) (Xiang and Brown 1998) that are hypothesized to
support long-term (24-h delay) memory. Muscarinic receptors
have been shown to be involved in perirhinal plastic processes
(Massey et al. 2001; Warburton et al. 2003), but the involvement
of nicotinic receptors in such perirhinal processes is unknown.
Studies of processes in other memory systems have reported that
certain neurons (Blum et al. 2009), receptors (McNamara et al.
2008), or intracellular pathways (Izquierdo et al. 2000b) support
distinct mechanisms for shorter- and longer-term memory.
In sum, our results indicate that (1) shorter- and longer-term
object recognition memory are dependent upon different choli-
nergic receptor types, and (2) that the effects of antagonism of
the two types of receptor within the perirhinal cortex are neither
independent nor additive. The findings present a challenge to
simple ideas about cholinergic actions in recognition memory.
Materials and Methods
Animals
Forty-seven male Dark Agouti rats (200–230 g; Bantin and
Kingman,Hull, UK)were used for object recognition experiments.
All of the animalswere housed under a 12-h light/dark cycle (light
phase, 18.00–06.00 h). Experiments were conducted during the
dark phase of the cycle. All animal procedures were performed
in accordance with the United Kingdom Animals Scientific
Procedures Act (1986) and University of Bristol Ethical Review
Group.
Object recognition following administration of
cholinergic antagonists
Surgery
Prior to testing in the novel object preference test (NOP) test, 25
rats underwent surgical procedures to implant guide cannulae
into the perirhinal cortex. Rats were anesthetized with isoflurane
(Merial, Harlow, UK) and placed in a stereotaxic frame with the
incisor bar set so as to achieve a horizontal skull. Craniotomies
were made 5.6-mm posterior and 4.5-mm lateral to bregma, and
10-mm length, 26-gauge stainless-steel guide cannulae (Plastics
One) were inserted 6.7 mm below the surface of the skull in the
coronal plane at an angle of 20˚ to the vertical. The cannulae
were attached to the surface of the skull by constructing an
implant made from bone cement (DePuy, UK) and attached to
the skull with stainless-steel screws (Plastics One). After surgery,
rats were allowed a 2-wk recovery period, during which they
were housed singly. Post-recovery, cannulated rats were housed
in pairs in large cages. Obdurators (Plastics One) were used to
keep the cannulae patent between infusions.
Novel object preference test (NOP) test
In a pretraining period, rats were habituated to an arena (length:
100 cm, depth: 100 cm, arena height: 40 cm) surrounded by cur-
tains, (height from arena base: 40–160 cm) in one 5-min period
each day for 4 d. For the novel object preference test (NOP) test,
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rats underwent an acquisition trial and choice trial separated by a
delay (20 min or 24 h). During the acquisition trial, each rat was
initially exposed to two identical copies of an object (Object A)
until it had explored the objects for .40 sec or had spent a max-
imumof 4 min in the arena. Objects were constructed fromDuplo
(Lego UK, Slough, UK) (length: 16 cm, depth: 16 cm, height:
12 cm). After a delay period of 20 min or 24 h, each rat was
exposed to another copy of Object A and a novel object (Object
B) in a choice trial lasting 3 min. In one preferential object recog-
nition memory experiment rats were placed in a Y-maze with the
objects positioned in two of the arms (see Supplemental Material;
Winters et al. 2006).
Infusions and intraperitoneal injections
Drugs
In each experiment, drug administration was either by a systemic
injection or by bilateral intracerebral infusion via guide cannulae
directed at the perirhinal cortex. Systemic administration was via
an intraperitoneal injection at a volume of 1 mL/kg given 30 min
prior to the acquisition trial. Rats received bilateral infusions into
the perirhinal cortex using 33-gauge infusion cannula (Plastics
One) inserted into the implanted guide cannula and attached to
a 25-mL Hamilton syringe by polyethylene tubing. An infusion
pump (Harvard Bioscience) was used to inject a volume of 1 mL
to each hemisphere during a 2-min period. Infusion cannulae
were kept in place for a further 5 min following the infusion.
Intracerebral drug infusions were given 15 min prior to acquisi-
tion trial, thereby allowing time for the systemic injections to be
effective, as in previous studies (Warburton et al. 2003; Winters
et al. 2006). The receptor antagonists used were methyllylcaconi-
tine (MLA), scopolamine hydrobromide, AFDX-384, and pirenze-
pine, all supplied by Tocris Biosciences (Bristol, UK). Previous
work with intracerebral infusions indicates that drugs may persist
at effective concentrations for 1 h post-infusion (Day et al.
2003).
Experiment 1. Dark Agouti rats were administered the nicotinic an-
tagonist methyllycaconitine (MLA) either systemically at a dose
of 87.5 mg/kg or via an intracerebral injection of 0.0875 ng/mL
(infusate ¼ 100 nM).
Experiment 2. A: Dark Agouti rats were administered the muscarinic
antagonist scopolamine hydrobromide systemically at a dose of
0.05mg/kg (arena). B: Dark Agouti rats were administered scopol-
amine hydrobromide via an intracerebral infusion (0.05 ng/mL)
(arena) (infusate = 130 nM).
Experiment 3. Dark Agouti rats were administered the nonselec-
tive muscarinic antagonist AFDX-384 at a dose of 12 ng/mL
(infusate ¼ 25 mM) intracerebrally.
Experiment 4. A: Dark Agouti rats were administered both MLA and
0.05 ng/mL of scopolamine. B: Dark Agouti rats were admin-
istered both MLA (0.0875 ng/mL) and AFDX-384 (12 ng/mL)
intracerebrally. In each part of Experiment 4, both compounds
were dissolved in the same saline solution and infused into the
perirhinal cortex as described above.
The dose forMLAwas selected so as not to produce deficits in
locomotion (Chilton et al. 2004). A high dose of AFDX-384 was
required with the aim of blocking all muscarinic subtypes, as
occurs with scopolamine (Dorje et al. 1991; Collison et al.
2000). Concentrations of infusate (or systemic doses) were chosen
to be 50–100 times that of the designated Ki value for the target
receptor to ensure maximal inhibition, but limit nonselective
effects. Ki values previously reported for the compounds used
are MLA(a7): 1 nM (Ivy Carroll et al. 2007), scopolamine (M1–
M5): 0.3–2 nM (Huang et al. 2001), and AFDX-384 (M1–M5):
6 nM–530 nM (Dorje et al. 1991). Half-lives for the drugs used
were: MLA ¼ 18 min (Stegelmeier et al. 2003), scopolamine ¼
3.7 h (Ebert et al. 1998), and AFDX-384 ¼ 40 min (Mickala et al.
1996).
Each experiment was run in two parts in a cross-over design.
In the first part, rats were randomly assigned an infusion/injec-
tion of drug or vehicle (0.9% saline for MLA, scopolamine; 0.2%
dimethyl sulfoxide (DMSO) in 0.9% saline for the AFDX-384)
and an object recognition experiment was performed. In the sec-
ond part, each rat was given the opposite infusate/injectate and a
second object recognition experiment was performed using new
objects. There was a minimum separation of 48 h between the
two parts of the experiment.
Data analysis
The time spent exploring each object was scored using a computer
program with the experimenter blind to the treatment.
Exploratory behavior was defined as the rat directing its nose
toward the object at a distance of ,2 cm; other behavior, such
as looking around while sitting on the object, was not considered
exploration. A discrimination ratio (DR) was used to measure
memory and was calculated by dividing the difference in time
exploring the novel and the familiar object by the time taken
exploring both objects. Rats that failed to complete a minimum
of a 10-sec exploration in the acquisition phase or a minimum
of 5 sec for the choice trial, were excluded from the analysis.
Over the course of the experiments, occasionally rats had to be
excluded from the analysis due to cannula failures.
Table 2 includes a summary of the rat groups included in the
statistical analysis of the drug experiments. Where rats were used
inmore than one experiment, the experiments were performed in
the following order. GroupC1: (1)MLA, 20 min, (2)MLA, 24 h, (3)
AFDX-384, 20 min, (4) AFDX-384, 24 h, (5) AFDX-384 & MLA,
20 min, and (6) AFDX-384 & MLA, 24 h. Group C2: (1) scopol-
amine, 20 min, (2) scopolamine and MLA, 24 h, and (3) scopol-
amine, 24 h. Discrimination ratios were analyzed using repeated
measures ANOVAwith factors treatment (drug/vehicle) and infu-
sion time. The significance level was P ¼ 0.05, two-tailed.
Verification of cannulae positions
Rats were anesthetized with Euthatal (Rhoˆne Me´rieux, Toulouse,
France) and transcardially perfused with 0.1 M phosphate buffer
containing formal saline, pH7.4. Coronal sections (40 mm) were
cut on a freezing microtome and the sections were stained with
cresyl violet. Cannula locations were compared with a stereotaxic
atlas (Paxinos and Watson 1998), and histological examination
confirmed that the tips of the cannulaewere within the perirhinal
cortex (Shi and Cassell 1999), see Figure 1A. Our cannula-tip
Table 2. Table showing animal groups used in each of the four experiments. Label denotes rat group and the number of animals in each
group is shown in brackets
Experiment 1 Experiment 2 Experiment 3 Experiment 4A Experiment 4B
Trial Delay MLA (ip) MLA (cannula) scop (infusion) scop (systemic) AFDX-384 MLA + Scop MLA + AFDX-384
Acquisition 20 min S1(11) C1(11) C2(12) S2(10) C1(9) C2(11) C1(8)
24 h S1(10) C1(12) C2(12) S2(9) C1(8) C2(12) C1(8)
Rat groupings: (S1) systemic group 1: Dark Agouti rats; (S2) systemic group 2: Dark Agouti rats; (C1) cannulated group 1: Dark Agouti rats; (C2) cannulated
group 2: Dark Agouti rats.
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locations matched the caudal region of the perirhinal cortex
(25.8 with respect to bregma) known to correlate with object rec-
ognition memory deficits (Albasser et al. 2009). Data from other
laboratories (Martin 1991; Izquierdo et al. 2000a; Attwell et al.
2001) and our data (Seoane et al. 2011) indicate that the infused
tissue extended to an 0.5–1 mm radius of the cannula tip.
This volume includes the majority of perirhinal cortex (Shi and
Cassell 1999), but only minor parts of neighboring entorhinal
cortex or area Te2.
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